Tasly Pharmaceutical Group Co., Ltd (SHA:600535)
China · Delayed Price · Currency is CNY 15.11
+0.13 (0.87%)
Apr 28, 2026, 3:00 PM CST
SHA:600535 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 8,257 | 8,147 | 8,468 | 8,636 | 8,606 | 7,898 |
Other Revenue | 89.1 | 89.1 | 29.81 | 37.71 | 31.19 | 53.86 |
| 8,346 | 8,236 | 8,498 | 8,674 | 8,637 | 7,952 | |
Revenue Growth (YoY) | -1.86% | -3.08% | -2.03% | 0.42% | 8.62% | -41.43% |
Cost of Revenue | 2,680 | 2,743 | 2,810 | 2,885 | 3,147 | 2,682 |
Gross Profit | 5,666 | 5,494 | 5,688 | 5,789 | 5,490 | 5,269 |
Selling, General & Admin | 3,377 | 3,306 | 3,334 | 3,326 | 3,267 | 3,339 |
Research & Development | 674.22 | 685.66 | 830.07 | 917.27 | 845.34 | 579.53 |
Other Operating Expenses | 110.73 | 105.82 | 87.98 | 96.46 | 37.96 | 110.64 |
Operating Expenses | 4,183 | 4,118 | 4,252 | 4,348 | 4,149 | 4,027 |
Operating Income | 1,483 | 1,375 | 1,437 | 1,441 | 1,341 | 1,243 |
Interest Expense | -32.5 | -32.5 | -61.28 | -82.52 | -64.86 | -77.39 |
Interest & Investment Income | 36.19 | 58.34 | 91.05 | 107.55 | 107.55 | 1,792 |
Currency Exchange Gain (Loss) | -1.06 | -1.06 | -1.07 | -1.23 | -1.61 | 7.27 |
Other Non Operating Income (Expenses) | 14.2 | -14.74 | -4.37 | -4.73 | -71.11 | 0 |
EBT Excluding Unusual Items | 1,499 | 1,385 | 1,461 | 1,460 | 1,311 | 2,965 |
Impairment of Goodwill | - | - | -15.88 | - | -151.2 | - |
Gain (Loss) on Sale of Investments | -84.68 | -31.35 | -213.45 | -282.81 | -1,125 | -79.88 |
Gain (Loss) on Sale of Assets | 1.32 | 8.61 | 2.11 | 0.15 | -4.93 | 41.27 |
Asset Writedown | -57.04 | -56.95 | -202.13 | -1.78 | -194.64 | -262.53 |
Other Unusual Items | 39.67 | 39.67 | 36.78 | 45.51 | -1.96 | 60.04 |
Pretax Income | 1,399 | 1,345 | 1,069 | 1,221 | -167.63 | 2,724 |
Income Tax Expense | 304.97 | 283.89 | 209.63 | 204.46 | 180.82 | 315.92 |
Earnings From Continuing Operations | 1,094 | 1,061 | 859.06 | 1,017 | -348.46 | 2,408 |
Minority Interest in Earnings | 67.1 | 43.63 | 96.53 | 54.43 | 84.22 | -48.75 |
Net Income | 1,161 | 1,105 | 955.59 | 1,071 | -264.24 | 2,359 |
Net Income to Common | 1,161 | 1,105 | 955.59 | 1,071 | -264.24 | 2,359 |
Net Income Growth | 19.11% | 15.63% | -10.78% | - | - | 109.51% |
Shares Outstanding (Basic) | 1,494 | 1,494 | 1,494 | 1,488 | 1,468 | 1,502 |
Shares Outstanding (Diluted) | 1,494 | 1,494 | 1,494 | 1,488 | 1,468 | 1,502 |
Shares Change (YoY) | 0.01% | - | 0.43% | 1.34% | -2.29% | 0.08% |
EPS (Basic) | 0.78 | 0.74 | 0.64 | 0.72 | -0.18 | 1.57 |
EPS (Diluted) | 0.78 | 0.74 | 0.64 | 0.72 | -0.18 | 1.57 |
EPS Growth | 19.10% | 15.63% | -11.16% | - | - | 109.33% |
Free Cash Flow | 1,978 | 1,043 | 1,450 | 1,907 | 1,875 | 2,229 |
Free Cash Flow Per Share | 1.32 | 0.70 | 0.97 | 1.28 | 1.28 | 1.48 |
Dividend Per Share | 0.310 | 0.310 | 0.530 | 0.330 | 0.330 | 0.330 |
Dividend Growth | -41.51% | -41.51% | 60.61% | - | - | - |
Gross Margin | 67.88% | 66.70% | 66.94% | 66.74% | 63.56% | 66.27% |
Operating Margin | 17.76% | 16.70% | 16.91% | 16.61% | 15.52% | 15.63% |
Profit Margin | 13.91% | 13.41% | 11.24% | 12.35% | -3.06% | 29.66% |
Free Cash Flow Margin | 23.70% | 12.67% | 17.06% | 21.98% | 21.71% | 28.04% |
EBITDA | 1,825 | 1,748 | 1,933 | 1,946 | 1,774 | 1,648 |
EBITDA Margin | 21.87% | 21.23% | 22.75% | 22.43% | 20.54% | 20.72% |
D&A For EBITDA | 342.38 | 373.14 | 496.2 | 504.91 | 433.92 | 405.08 |
EBIT | 1,483 | 1,375 | 1,437 | 1,441 | 1,341 | 1,243 |
EBIT Margin | 17.76% | 16.70% | 16.91% | 16.61% | 15.52% | 15.63% |
Effective Tax Rate | 21.80% | 21.10% | 19.62% | 16.74% | - | 11.60% |
Revenue as Reported | 8,236 | 8,236 | 8,498 | 8,674 | 8,637 | - |
Updated Mar 31, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.